Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29639033 | 1.00 | PTK2 (0.44) | PTK2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL11468902 | 0.88 | AR (0.42) | PTK2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL832574 | 0.87 | ALDH1A1 (0.43) | PTK2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL13375163 | 0.87 | GRIA1 (0.38) | PTK2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3107558 | 0.85 | GRIN2D (0.37) | PTK2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL5951712 | 0.83 | ALDH1A1 (0.52) | PTK2POLBHTTNOS3NOS1 | |
| SCHEMBL13375174 | 0.83 | POLB (0.36) | PTK2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL5382583 | 0.81 | AR (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8729779 | 0.81 | ALDH1A1 (0.44) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL10545243 | 0.81 | POLB (0.38) | PTK2GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024038810-A1 | POSITIVE-TYPE PHOTOSENSITIVE COMPOSITION, CURED FILM, ORGANIC EL DISPLAY DEVICE, AND COLORANT | 東レ株式会社 | 2024-02-22 | — | — | WO | disclosed |
| CN-117043676-A | Positive photosensitive pigment composition, cured film containing cured product thereof, and organic EL display device | 东丽株式会社 | 2023-11-10 | — | — | CN | disclosed |
| WO-2022270182-A1 | POSITIVE PHOTOSENSITIVE PIGMENT COMPOSITION, CURED FILM CONTAINING CURED PRODUCT THEREOF, AND ORGANIC EL DISPLAY DEVICE | 東レ株式会社 | 2022-12-29 | — | — | WO | disclosed |
| CN-113087674-B | Method for synthesizing quinoxaline compound under catalysis of visible light induced photosensitizer | 河南大学 | 2022-06-17 | — | — | CN | disclosed |
| CN-113087674-A | Method for synthesizing quinoxaline compound under visible light induced iron catalysis condition | 河南大学 | 2021-07-09 | — | — | CN | disclosed |
| US-20120277433-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED QUINOXALINES | ALKEM LABORATORIES LIMITED (IN) | 2012-11-01 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20080275051-A1 | Preparation of High Purity Substituted Quinoxalines | BUSCH FRANK R | 2008-11-06 | — | — | US | disclosed |
| US-5795889-A | INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5698135-A | POLYAMIC ACID OBTAINED FROM REACTION OF DIANHYDRIDE OF SPECIFIED TETRACARBOXYLIC ACID AND OF CYCLOBUTANETETRACARBOXYLIC ACID WITH DIAMINE, OR POLYMER OBTAINED BY IMIDIZING SAID POLYAMIC ACID | JAPAN SYNTHETIC RUBBER CO., LTD., A JAPANESE CORPORATION (JP) | 1997-12-16 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5631373-A | NERVOUS SYSTEM DISORDERS | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-05-20 | — | — | US | disclosed |
| EP-0770688-A1 | Method of quantitative determination of bilirubin and a reagent therefor | KYOWA MEDEX CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
| EP-0732942-A1 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | ACEA PHARMACEUTICALS, INC. (US) | 1996-09-25 | — | — | EP | disclosed |
| EP-0718666-A1 | Liquid crystal-aligning agent | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 1996-06-26 | — | — | EP | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
| WO-1995012417-A1 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | ACEA PHARMACEUTICALS, INC. (US) | 1995-05-11 | — | — | WO | disclosed |
| US-4301171-A | 2-(1,4-Benzodioxan-2-ylalkyl)benzimidazoles useful as anti-depressants | SYNTEX (U.S.A.) INC. (US) | 1981-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275051-A1 | Preparation of High Purity Substituted Quinoxalines | QDPR, NQO2, NDUFA7 | PTK2 4071/4885GRIN2D 1308/4885GRIN3B 1769/4885 |
| US-20120277433-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED QUINOXALINES | QDPR, DCXR, NQO2 | PTK2 3398/4885GRIN2D 1062/4885GRIN3B 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.